Kratak sadr`aj: Primena metotreksata (MTX) u viso kim dozama i/ili intratekalno u terapiji malignih obo ljenja poput akutne limfoblasti~ne leukemije (ALL) povezana je sa pojavom blagih ili te{kih oblika neuro toksi~nosti. Patogeneza neurotoksi~nosti nije u potpu nosti razja{njena, ali se va`na uloga pripisuje biohe mijskim promenama folatnog i metiltransfernog meta boli~kog puta za koje se smatra da su uzrokovane dejstvom MTX. Opisujemo slu~aj odrasle pacijen tkinje na terapiji recidiva ALL sa simptomima hroni~ne leukoencefalopatije najverovatnije uzrokovane primenom MTX. U cilju procene folatnog i metil-transfernog puta u cere brospinalnoj te~nosti (CST) pacijentkinje merene su koncentracije 5-metiltetrahidrofolata (5-metil-THF), S-adenozilmetionina (SAM) i S-adenozilhomocisteina (SAH). Tri uzorka CST su dobijena lumbalnom punkcijom u periodu od ~etiri meseca. Koncentracije su merene pomo}u validiranih bioana liti~kih metoda zasnovanih na primeni HPLC sa ultraljubi~astom i fluorescentnom detekcijom. Rezultati su pokazali dvostruko sni`enje koncentracije 5-metil-THF (29.3-31.8 nmol/L) u pore|enju sa referentnim vrednostima u svim uzor cima, dok su koncentracije SAM bile pet puta manje u dva uzorka (5-34.2 nmol/L). Koncentracije SAH su bile u rasponu 7.5-14.3 nmol/L. Na{a pacijentkinja je imala izra`ene promene u folatnom i metil-transfernom metaboli~kom putu koje uka zuju na to da biohemijske promene ovih metaboli~kih puteva za koje se smatra da su uzrokovane dejstvom MTX mogu igrati va`nu ulogu u razvoju leuko encefalopatije.
Summary: Intrathecal and/or high-dose intravenous administration of methotrexate (MTX) in the treatment of malignancies such as acute lymphoblastic leukaemia (ALL) has been associated with cases of mild to severe neurotoxicity. The pathogenic mechanism of neurotoxicity is not clear, possibly MTX-associated biochemical alterations of the folate and methyl-transfer metabolic pathways play an important role. We report a case of an adult patient treated for ALL relapse with signs of chronic leukoencephalopathy associated with MTX administration. In order to assess alterations in the folate and methyl-transfer pathway we determined 5-methylte trahydrofolate (5-methyl-THF), S-adenosylmethi onine (SAM) and S-adenosylhomocysteine (SAH) in the cerebrospinal fluid (CSF) of the patient. Three CSF samples were obtained by lumbar punction within a four-month period. Concentrations of the metabolites were measured using validated bioanalytical methods based on HPLC with UV and fluorescence detection. The results showed two-fold lower 5-methyl-THF levels (29.3-31.8 nmol/L) in all obtained sam ples compared to reference values. SAM concentrations were even more than five-fold lower in two samples (5-34.2 nmol/L). SAH concentrations were in the range 7.5-14.3 nmol/L. Our patient had pronounced alterations in the folate and methyltransfer pathway which indicate that MTX-associated biochemical alterations of these pathways may play an important role in the development of leukoence pha lopathy.
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Case report
Intrathecal and/or high-dose (>1 g/m 2 ) administra tion of methotrexate has been associated with neurotoxicity (1, 2), which in terms of severity ranges from mild and reversible to severe with possible fatal outcome (3). According to time of appearance, neurot o xicity is classified as acute, subacute and chronic. Clinical signs of chronic neurotoxicity may appear months to years following MTX administration (4) . This form of neurotoxicity, although rare, is usually severe, char a cterized by leukoencephalopathy, demyelination, loss of cerebral parenchyma (4, 5) and clinical signs such as personality changes, progressive dementia, focal seizures, spastic quadriparesis and stupor (4) . Patients may also develop learning disability, cognitive disturbances and decrease in intelligence (6, 7) . Chro nic MTX-associated neurotoxicity may resolve partially or fully, but it may also persist and even progress to coma and death (8, 9) .
The pathogenic mechanisms of MTX-associated neurotoxicity are not fully elucidated yet (10) . It was suggested that MTX-induced biochemical alterations may play an important role in the development of neurological complications (11) .
MTX as an antifolate targets primarily the folate pathway (see Figure 1 ) inducing the depletion of the pool of tetrahydrofolates (THF). Accordingly, decreased levels of 5-methyl-THF were reported in the CSF of patients who received high-dose or intraventricular MTX (11, 12) . However, the mechanism by which folate depletion could induce neurotoxicity is unclear. It is possible that other metabolic pathways which are altered as a consequence of folate impairment may be responsible for clinical signs of neurotoxicity.
The folate metabolic pathway is directly linked to the homocysteine-methionine conversion through 5-met hyl-THF. The lack of methionine leads to a depletion of the main methyl-donor S-adenosylmethionine (SAM). SAM together with the methyl-transferase inhibitor S-adenosylhomocysteine (SAH) forms the methyl-transfer pathway which is necessary for methylation and synthesis of the myelin sheath. Loss of myelin disables the normal neuronal function which could further lead to the development of cognitive decline. Since severe demyelination and white matter changes are main features of chronic MTX-associated neurotoxicity, an impairment of the methyl-transfer pathway may be involved in its pathogenesis. Moreover, decreased SAM levels in the CSF were associated with demyelination reported in patients with MTX-related subclinical and clinical leukoencephalopathy (13, 14) . Furthermore, it was suggested that the SAM/SAH ratio may be a better marker for leukoencephalopathy than SAM alone (15) . We report a case of a patient suffering from chronic MTX-associated neurotoxicity presenting with leukoencephalopathy, manifest signs of cognitive disorder and personality change with a severe impa irment of the folate and methyl-transfer pathway.
Our patient was a 35-year old female with ALL which was first diagnosed at the age of 17. At that time she was treated with high-dose MTX accompanied by cranial irradiation. At the age of 27, the first relapse occurred and the patient was treated with high-dose MTX (1 g/m 2 ) and intrathecal MTX (12 mg) without cranial irradiation. A total of nine high-dose infusions and 60 mg intrathecal MTX were administered. At that time no MTX-associated neurological complications were observed. At the age of 35, she presented with the second relapse and started receiving treatment which did not include MTX. However, at this timepoint, cognitive decline, memory loss, confusion, depres sed level of consciousness, personality change, speech impairment and tremor were evident. The evaluation of neurotoxicity was performed according to Common Toxicity Criteria (CTC) and the results are presented in Table I . Magnetic resonance imaging (MRI) revealed severe leukoencephalopathy in both brain hemisph e res. Circular lesions were also present, however, asso ciated with an overt infection.
According to a previously obtained approval of the local ethics committee we were able to obtain CSF samples when lumbar puncture was performed diagnostically or due to the treatment protocol. Three CSF samples were obtained within four months. The third sample was obtained when the patient presented with signs of toxicity probably due to a CNS infection. She had severe headache and pain followed by high fever. The CSF was yellow coloured indicating hyperbilirubinemia which was later confirmed.
In order to assess the folate pathway, 5-methyl-THF was determined using a modified method by Belz et al. (16) from Supelco (Bellefonte, USA) were used as stationary phase. The HPLC system was from Thermo Separation Products, Inc (Egelsbach, Germany). Fifty mL samples were injected onto the HPLC system and separated by gradient elution which consisted of methanol and phosphate buffer (10 mmol/L, pH 2.1). Fluorescence detection (294/356 nm) was used, flow rate was 1 mL/min, retention time was 8.8 min. The method was validated according to the FDA Guideline (17) . Due to the instability of reduced folates, CSF samples were collected in vials containing an ascorbic acid solution (5 mg/mL).
Determination of SAM and SAH in the CSF was performed using HPLC with fluorescence detection. An Eclipse TM AAA column (15 x 0.46 cm, 5 mm) from Agilent Technologies Inc., (Palo Alto, USA), and a Nucleosil TM precolumn (2 x 0.46 cm, 5 mm) from Supelco (Bellefonte, USA) were used as stationary phase. Fluorescence detection of SAM and SAH was enabled by derivatisation with 5.5 mol/L chloroacetaldehyde at pH 3.5-4.0, 39 °C for 16 h as described by Wagner et al. (18) . The formed 1,N 6 -etheno derivatives were eluted on a reversed phase column especially designed for separation of amino acids. Mobile phase consisted of acetonitrile and an aqueous solution (pH 4.5) containing 40 mmol/L of potassium dihydrogen pho s phate and 8 mmol/L of the ion-pair reagent 1-hepta nesulfonic acid. Analytes were separated by gradient elution. The injection volume was 100 mL, at a con - (17) .
CSF concentrations of 5-methyl-THF, SAM and SAH of the patient with chronic neurotoxicity are presented in Table II . Our patient had approximately twofold lower CSF 5-methyl-THF concentrations compared to normal CSF levels according to literature data (19, 20) . Moreover, we previously reported CSF 5-methyl-THF concentrations in adult patients with primary central nervous system lymphoma (PCNSL) treated with high-dose and intrathecal MTX (21) . Our ALL patient with chronic neurotoxicity had considerably lo wer CSF 5-methyl-THF concentrations compared to PCNSL patients without neurotoxicity (see Table II ). Furt hermore, in the PCNSL population we had a patient with signs of chronic neurotoxicity and leukoencephalopathy with massive demyelination revealed by MRI. Low 5-methyl-THF concentrations similar to those found in the present case were observed in this patient as well (Table II) .
CSF SAM concentrations were at least five-fold lower in two out of three samples compared to literature reference data (22) . In the last sample the level of SAM was rather high compared to the two previous measurements. However, at that time-point the patient exhibited hyperbilirubinemia and the CSF sample was intensively yellow coloured. It cannot be excluded that there was an interference with the fluorescence determination of SAM.
CSF SAM levels in the first two samples of our present patient were also considerably lower compared to PCNSL patients without neurotoxicity. Moreover, present findings are similar to CSF SAM levels in the PCNSL patient at the time of chronic neurotoxicity. In contrast, CSF SAH levels in our patient were similar to those of PCNSL patients where the level of the methyltransferase inhibitor ranged from 5.1-11.0 nmol/L (21). Kishi et al. (15) also reported two cases with chronic neurotoxicity who had low CSF SAM levels (74.8 and 79.3 nmol/L respectively). However, in contrast to our findings, these authors also reported increased SAH levels (27.5-34.3 nmol/L).
In conclusion, a severe biochemical alteration of the folate and methyl-transfer pathways was observed in an ALL patient with chronic MTX-associated neurotoxicity. Since SAM is the most important methyl-donor, the impairment of the methyl-transfer pathway which resulted in more-fold decreased CSF SAM levels could have played a crucial role in the pathogenesis of le ukoencephalopathy. Further research is necessary to establish if monitoring of the 5-methyl-THF and SAM in the CSF may help predict patients at risk of developing signs of chronic neurotoxicity. Moreover, if the impairment of the methyl-transfer pathway is respon sible for demyelination, then substitutional therapy with SAM may represent an option for preventing neuronal dama ge and its consequences.
